Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2004 Sep 20;200(6):771–782. doi: 10.1084/jem.20041130

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2004, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Concomitant immunity to B16 is shared with JBRH melanoma, but not with Lewis lung carcinoma or LiHa fibrosarcoma. Mice were inoculated (left flank) on day 0 with either Lewis lung carcinoma (A), LiHa fibrosarcoma (B), or JBRH melanoma (C). Mice were either untreated; depleted of CD4⁺ T cells on days −2, 4, and 11; or depleted of CD4⁺ T cells on days −2, 4, and 11 and inoculated with B16 tumors (right flank) on day −6 to induce concomitant immunity. Tumor diameter represents the mean of the greatest diameters (± SEM) for 15 mice/group. For JBRH tumors, the difference between mean sizes in naive versus B16 tumor-bearing mice was statistically significant (P < 0.05; by two-tailed Student's t test) at all time points between days 12 and 20.